Genomic Insights for Personalized Care: Motivating At-Risk Individuals Toward Evidence-Based Health Practices

3

4 Tony Chen^{1,*}, Giang Pham², Louis Fox², Jingning Zhang³, Jinyoung Byun⁴, Younghun

5 Han⁴, Gretchen R.B. Saunders⁵, Dajiang Liu⁶, Michael J. Bray^{7,8}, Alex T. Ramsey², James

- 6 McKay⁹, Laura Bierut², Christopher I. Amos^{4,10}, Rayjean J. Hung¹¹, Xihong Lin^{1,12}, Haoyu
- 7 Zhang^{13,†,*}, Li-Shiun Chen^{2,†,*}
- 8
- ⁹ ¹ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA
- ² Department of Psychiatry, Washington University School of Medicine, St. Louis, USA
- ³ Regeneron Genetics Center, Tarrytown, NY, USA
- ⁴ Department of Medicine, Section of Epidemiology and Population Science, Institute for
- 13 Clinical and Translational Research, Houston, TX, USA
- ⁵ Department of Psychology, University of Minnesota, Minneapolis, MN, USA
- ⁶ Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA,
- 16 USA
- ¹⁷ ⁷ Department of Genetic Counseling, Bay Path University, Longmeadow, MA, USA
- 18 ⁸ ThinkGenetics, Inc, USA
- ⁹ International Agency for Research on Cancer, World Health Organization, Lyon, France
- ¹⁰ Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston,
- 21 TX, USA
- ¹¹ Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research
- 23 Institute, Sinai Health, and University of Toronto, Toronto, Canada
- ¹² Department of Statistics, Harvard University, Cambridge, USA
- ¹³ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda,
- 26 MD, USA
- 27
- 28 *Correspondence to: Tony Chen (<u>tonychen@g.harvard.edu</u>), Haoyu Zhang
- 29 (haoyu.zhang2@nih.gov) and Li-Shiun Chen (li-shiun@wustl.edu).
- 30 †These authors jointly supervised this work: Haoyu Zhang and Li-Shiun Chen.

31 Abstract

32 Lung cancer and tobacco use pose significant global health challenges and require a comprehensive translational roadmap for improved prevention strategies. We propose 33 the GREAT care paradigm (Genomic Informed Care for Motivating High Risk Individuals 34 35 Eligible for Evidence-based Prevention), which employs polygenic risk scores (PRSs) to stratify disease risk and personalize interventions, such as lung cancer screening and 36 37 tobacco treatment. We developed PRSs using large-scale multi-ancestry genome-wide association studies and adjusted for genetic ancestry for standardized risk stratification 38 39 across diverse populations. We applied our PRSs to over 340,000 individuals of diverse ethnic background and found significant odds ratios for lung cancer and difficulty guitting 40 smoking. These findings enable the evaluation of PRS-based interventions in ongoing 41 trials aimed at motivating health behavior changes in high-risk patients. This pioneering 42 approach enhances primary care with genomic insights, promising improved outcomes in 43 44 cancer prevention and tobacco treatment, and is currently under assessment in clinical 45 trials.

47 Introduction

48 The worldwide burden of lung cancer and tobacco smoking presents major challenges to global health¹. Evidence-based practices to reduce their risk such as cancer 49 50 screening and tobacco treatment (e.g. smoking cessation medication) have long existed 51 but are infrequently used in most primary care practices. Communication of the precision 52 risk of lung cancer and precision benefit of smoking cessation is a promising but untested 53 strategy to promote health behavior changes to reduce cancer risk. To address this gap, 54 polygenic risk scores (PRSs) emerge as a valuable approach to assess disease susceptibility among populations and pinpoint individuals at higher risk^{2–4}. PRSs can be 55 derived from large-scale genome-wide association studies (GWAS) to estimate individual 56 57 disease risk and have shown promise in predicting health outcomes and promoting preventive healthcare^{5–9}. Despite their potential, PRSs' implementation in primary care is 58 59 limited, especially in diverse populations. Implementing a PRS-based precision 60 intervention is crucial in order to address the multifaceted needs of different communities and individuals. Harnessing PRSs effectively can make significant progress in mitigating 61 62 lung cancer's public health impact.

Ongoing studies like eMERGE¹⁰, GenoVA¹¹, and WISDOM¹² are leading the 63 64 implementation of PRS into genetic risk reports (Table 1). They aim to personalize medical reports and understand the impact of PRS on screening, diagnostic procedures, 65 and patient behavior. Notably, a gap persists as these initiatives have not yet formulated 66 a PRS specifically for lung cancer. A likely reason is that the global burden of lung cancer 67 is primarily driven by tobacco smoking rather than genetics^{13,14}. However, accounting for 68 69 the genetic basis of lung cancer may provide patients and clinicians with additional 70 actionable information. The unique value proposition of a lung cancer-specific PRS lies 71 in leveraging established and clear guideline-based prevention strategies, including smoking cessation treatment and lung cancer screening¹⁵. By incorporating PRSs for lung 72 73 cancer and difficulty quitting smoking without treatment, there is an opportunity to 74 revitalize and enhance these often under-utilized prevention practices.

75 We introduce the Genomic Informed Care for Motivating High Risk Individuals 76 Eligible for Evidence-based Prevention (GREAT) framework as a novel approach to 77 incorporate PRS-enabled interventions in clinical settings (Figure 1). The core of GREAT 78 is the use of PRSs that offer precise risk estimates for lung cancer and difficulty guitting. 79 By providing patients with personalized risk information, we aim to activate behavior 80 change mechanisms that promote preventive actions. The primary targets of this 81 intervention are high-risk individuals eligible for evidence-based prevention practices, such as lung cancer screening and smoking cessation. By integrating precision risk 82 information with the benefits of timely interventions, GREAT empowers patients to make 83 informed decisions about their health and motivates them to take proactive steps towards 84 85 prevention. Ultimately, our objective is not only to motivate, but to significantly reduce lung 86 cancer morbidity and mortality through this innovative care paradigm.

Effectively translating PRSs into clinical practice requires a comprehensive and 87 88 pragmatic translational roadmap for equitable and effective implementation (Figure 1). 89 First, to address ancestry diversity, we take a two-step approach of (1) constructing PRS based on large-scale multi-ancestry GWAS, and (2) standardizing PRS distributions 90 91 across the continuum of genetic ancestry^{16,17} by leveraging reference data from the 1000 Genomes Project Phase 3 (1000G)¹⁸. Given the variations in allele frequencies (AF) and 92 93 linkage disequilibrium (LD) across ancestries, this step is critical to ensure fair risk stratification based on PRS distributions^{10,19}. Second, to document accuracy and 94 transportability of the PRSs to diverse populations, we perform large-scale validation 95 using data from individuals of diverse self-reported ethnicities in the UK Biobank (UKBB) 96 97 and Genetic Informed Smoking Cessation (GISC) trial. Third, we translate risk into 98 actionable categories by setting appropriate thresholds for the PRS. The alignment of 99 these thresholds with clinical significance involves many considerations for meaningful 100 risk stratification. Fourth, we propose clear and patient-friendly communication strategies, 101 including visual aids and educational materials, to facilitate understanding and meaningful interactions between patients and healthcare providers. Effectively communicating both 102 103 the risk and precision of the PRS results is challenging but essential to empower patients 104 to make informed decisions about their health. Moreover, it is crucial to consider patient perceived risk, perceived benefit, and personal relevance when discussing PRS results 105 with patients. Patients' understanding and interpretation of PRS may vary, leading to 106 differing levels of engagement in preventive actions. Hence, comprehensive patient 107 education programs can enhance awareness and knowledge about PRS, its implications, 108 109 and available preventive measures.

110 In this paper, we introduce the design for two cluster randomized clinical trials 111 (RCT): (1) PRECISE, which evaluates the effectiveness of a multilevel intervention, 112 RiskProfile, on increasing lung cancer screening and tobacco treatment utilization in 113 primary care (NIDA Grant 5R01CA268030-02); and (2) MOTIVATE, which evaluates the 114 effect of PrecisionTx, a multilevel intervention to promote precision tobacco treatment in 115 primary care (NIDA Grant 5R01DA056050-02). Through the innovative use of PRS, our aim is to motivate lung cancer screening and tobacco treatment among high-risk patients. 116 117 We present a new care paradigm (Figure 1) and outline a translational roadmap (Figure 118 2) that discusses potential barriers and solutions for implementation. By incorporating 119 personalized risk assessments, such PRS-enabled interventions have the potential to 120 significantly improve lung cancer prevention strategies and patient outcomes.

121

122 **Results**

123 Sample Characteristics

For primary validation, we used data from 340,154 unrelated individuals in the UK Biobank (UKBB)²⁰, given its large sample size, rich clinical data, and inclusion of individuals from diverse ancestry backgrounds (**Methods**). Lung cancer validation involved 1,830 cases and 338,324 controls across five self-reported ethnic backgrounds: European (EUR, N = 318,043, N_{case} = 1,762), African (AFR, N = 6,409, N_{case} = 19), East Asian (EAS, N = 599, N_{case} = 2), and South Asian (SAS, N = 7,520, N_{case} = 10), with 7,583 (N_{case} = 37) with "Other" self-reported ethnic backgrounds such as mixed or unknown (**Supplementary Table 1a**). Lung cancer occurrence was slightly higher among men (53.3% of cases) compared to women (46.7% of cases).

For difficulty quitting, the cohort comprised 34,923 current smokers and 117,483 individuals who had previously smoked. The breakdown by self-reported ethnicity for this analysis was as follows: EUR (N = 145,483, 95.4%), AFR (N = 1,874, 1.2%), EAS (N = 131, 0.1%), and SAS (N = 1,733, 2.2%) (**Supplementary Table 1b**). Among those who had quit smoking, 50.3% were male among Europeans, while quitting in non-European males varied between 51.2% and 81.5%.

In addition, we validated the PRSs using data from the Genetically Informed Smoking Cessation (GISC) trial, which more accurately reflects the patient demographics anticipated in the PRECISE and MOTIVATE trials. The difficulty quitting analysis encompassed 647 current smokers and 149 former smokers, with the ancestry distribution as follows: 503 of European descent, 257 of African descent, and 36 of other ancestries (**Supplementary Table 1c**).

145

146 Harmonization PRS distributions across ancestry

147 To harmonize the polygenic risk scores (PRS) across diverse ancestries, we first 148 projected genotypes of individuals from the UKBB and GISC onto a principal components 149 analysis (PCA) space using PC loadings derived from 55,248 variants within 1000G 150 dataset (Methods). The resulting PC scores aligned closely with the continental ancestries represented in the 1000G, confirming that projecting genotypes to an 151 152 externally-defined PC-space still maintains similar clustering by ethnicity (Figure 3). The 153 SNPs used and their corresponding loadings for the top five PCs are detailed in 154 Supplementary Table 4.

155 We constructed PRSs for lung cancer and smoking cessation using large multiancestry GWAS with publicly accessible summary statistics (Methods, Supplementary 156 157 Tables 2-3). Variations in the raw PRS across ancestries were notable (Figure 4). For 158 instance, only 6% of AFR individuals in the UKBB cohort had a raw lung cancer PRS above the 80th percentile when benchmarked against the 1000G distribution. Conversely, 159 57% of EAS individuals ranked below the 33rd percentile for the difficulty guitting PRS 160 161 (Supplementary Table 6a-b). Such differences indicate that applying a universal cutoff for PRS without ancestry adjustment could lead to skewed risk profiling and inaccurate 162 clinical recommendations. Even with the smaller sample size of the GISC dataset, there 163 were noticeable difference in PRS distribution similar to those in the UKBB data 164 165 (Supplementary Tables 6c-d).

To address this, we use a two-step ancestry adjustment procedure that regresses 166 167 out ancestry PCs from the raw PRS such that the mean and variance of the PRS 168 distribution are consistent across all populations (Methods, Figure 4, Supplementary Table 5). This adjustment step places individuals from different ancestries on a 169 170 standardized scale, enabling the use of a single risk stratification cutoff irrespective of an 171 individual's ancestral background. After ancestry adjustment, the corresponding 172 proportions of the UKBB individuals within each risk category closely match 20%-60%-173 20% for lung cancer, and 33.3%-33.3%-33.3% for difficulty quitting, so that patients of 174 any background can be appropriately compared against a single reference distribution for each outcome (Supplementary Table 6a-b). 175

176

177 Risk stratification for lung cancer and smoking cessation

178 All participants receiving interventions in our two ongoing trials are high-risk 179 primary care patients who meet the criteria for lung cancer screening with elevated risks of lung cancer. Thus, we will assign patients to one of three PRS-based risk categories -180 "at risk", "high risk", and "very high risk" – using percentile cutoffs of ancestry-adjusted 181 PRS distributions based on 1000G. To quantify patient risk, we calculated odds ratios 182 183 (ORs) relative to the "at risk" group using 350,154 UKBB participants for lung cancer and 152,406 for difficulty guitting (Figure 5, Supplementary Tables 4-5). For lung cancer, 184 individuals within the 0-20th percentiles of the adjusted PRS distribution were categorized 185 as "at risk", those in the 20-80th percentiles as "high risk", and the 80-100th percentiles 186 as "very high risk". These percentiles yielded overall ORs of 1.42 (95% CI: 1.24 - 1.65) 187 188 for "high risk" and 1.85 (95% CI: 1.58 - 2.18) for "very high risk" group compared to the "at risk" group (Supplementary Table 7a). Notably, the ORs derived from our ancestry-189 190 adjusted PRS were nearly identical to those obtained by matching individuals' raw PRS 191 values with ancestry-specific distributions in 1000G (Supplementary Table 7b). This 192 indicates that ancestry adjustment not only preserves similar results as the ancestry-193 matched approach but also crucially supports the inclusion and robust risk stratification 194 of individuals with mixed or unknown ethnic backgrounds.

195 However, differences in ORs were still observed between EUR and non-EUR 196 participants, potentially due to the limited number of non-EUR cases (67 out of 1,830 total 197 lung cancer cases) in the UKBB cohort, which is predominantly EUR. The OR for the EUR 198 "very high risk" group was 1.85 (95% CI: 1.57 – 2.19), which is consistent with the 199 combined odds ratios across all ancestries (Supplementary Table 7a). The OR for all 200 non-EUR samples in the "very high risk" category was modestly reduced to 1.63 (95% CI: 0.78 – 3.51) (Supplementary Table 7b). Given the small number of non-European cases, 201 202 enhanced diversity in biobank-scale validation data should better illustrate the difference 203 in risk stratification between raw and ancestry-adjusted PRS.

Since difficulty quitting is a behavior trait with no established absolute risk rates like cancer, we use terciles (0-33rd, 33rd-67th, and 67-100th percentiles) of the ancestry-

adjusted PRS distribution to provide provides with slightly more agnostic risk information. 206 207 The resulting ORs among UKBB participants were 1.19 (95% CI: 1.15 – 1.22) for "high risk" and 1.36 (95% CI: 1.32 - 1.41) for "very high risk" relative to "at risk" 208 209 (Supplementary Table 8a-b). Further validation using smoking status outcomes from the 210 GISC trial assessed showed higher overall ORs in both risk categories, but risk 211 stratification using the ancestry-adjusted PRS distribution still reflected similar odds ratios 212 as ancestry-matched PRS distributions (Supplementary Table 9a-b). However, since the 213 GISC trial have much smaller sample size compared to UKBB, the confidence intervals 214 were notably wider. Similar to the lung cancer analysis, the ORs using our ancestryadjusted PRS aligned closely those derived from ancestry-matched raw PRS. 215

Using ancestry-adjusted PRS ensures equitable risk stratification across all ethnic backgrounds, a critical consideration given the substantial variability in raw PRS distributions across diverse populations (**Figure 4**). The outcome-based validation in UKBB and GISC further verify that the ancestry-adjusted PRS yields valid risk stratification. These findings collectively facilitate more robust and standardized application of PRS in clinical reporting.

222

223 Translating polygenic risk scores into clinical reports

224 We highlight two example trials: PRECISE (NIDA Grant 5R01CA268030-02) and MOTIVATE (NIDA Grant 5R01DA056050-02), designed to promote health behavior 225 226 change using genetically-informed interventions, RiskProfile and PrecisionTx, 227 respectively. These interventions incorporate PRS in communicating precision risk of lung 228 cancer and precision benefits of smoking cessation to promote evidence-based practices 229 such as cancer screening and tobacco treatment in high-risk individuals who smoke 230 and/or are eligible for lung cancer screening. PRS risk stratification from either RiskProfile 231 or PrecisionTx and clinical information are delivered within a comprehensive report, along 232 with actionable recommendations to reduce lifetime risk (Figure 6). Access to 23 and me 233 genotypes and expanded health information has been a motivating component for the 234 research participants. Both PRECISE and MOTIVATE are currently in the preliminary 235 phases of recruiting primary care providers and patients. The recruitment strategy aims 236 to engage over 100 physicians and 1600 patients in these trials.

237

238 Discussion

In this study, we introduce the GREAT framework in primary care. The application of PRSs in the two example trials offers precise risk estimates for lung cancer and difficulty quitting to high-risk individuals to activate behavior change mechanisms that promote health. To enable the interventions, we present a feasible translational roadmap to transform genetic data, implemented in two example PRS-enabled interventions designed to promote health behaviors. These behavior-change tools will be evaluated for implementation and effectiveness in motivating patients at high risk to reduce their risk byincreased cancer screening and smoking cessation.

247 Importantly, we have accomplished our goals of generating behavior-change 248 interventions by a) framing our translational message specifically for high-risk patients 249 who have not received guideline-recommended cancer screening or tobacco treatment^{21–} 250 ²⁴, b) translating risk categories into precision risk and benefit that are designed to 251 motivate health behavior changes, and c) ensuring inclusion of diverse ancestry with PC-252 regression-based PRS adjustment.

Our goal is to enable a robust implementation of PRS in currently funded clinical trials to evaluate the efficacy of these relatively novel interventions. The GREAT framework guides the implementation of PRS-enabled interventions in primary care settings. Critical questions such as timing, methodology, and location of these interventions' delivery to patients and providers are addressed to optimize its acceptability, understanding, and potential impact.

259 Our approach to ancestry adjustment of PRS employs widely accessible data from the 1000G dataset, as an alternative to methods in the GenoVA¹¹ and eMERGE¹⁰ studies 260 that use data from the Mass-General Brigham Biobank and All of Us, respectively. We 261 262 have validated the transferability of our 1000G-based standardization in external datasets from the UKBB and GISC, allowing future trials to adopt a similar methodology 263 irrespective of their specific genetic data. By utilizing our provided PC loadings and PRS 264 standardization formula for lung cancer and difficulty guitting based on 1000G data, new 265 266 patients in these trials can receive accurate risk categorization reports, bypassing the 267 potential inaccuracies of self-reported ethnicity and the need for re-training PCA models.

A notable gap in current practice is the absence of genetic information in electronic 268 269 health records (EHRs) for decision support and the lack of PRS generation in clinical labs. 270 Implementing multilevel precision interventions in primary care necessitates a workflow 271 that incorporates the use of EHRs for recruitment, protocols of biomarker testing, and a standardized process to generate the personalized intervention reports²⁵. This requires 272 collaborations with primary care stakeholders, community advisory boards, genetic 273 274 counseling, and health communication to improve the messaging and visualization for intervention clarity, accuracy, and impact^{26–30}. Patients expressed a notable interest in 275 receiving personalized interventions. In our previous study, 85% of smoking patients 276 277 reported a high interest in receiving genetically tailored tobacco treatment³¹. Further, a 278 substantial majority (95%) of individuals who smoke endorsed the importance of receiving 279 genetic results, in particular to guide their treatment²⁷. Following receipt of a personalized 280 genetic risk profile for smoking cessation, 91% of participants who smoke found the tool to be highly useful, most notably to better understand their health, cope with health risks, 281 and feel more in control of their health²⁸. Such pronounced interest and the perceived 282 283 significance of genetic data highlight the growing demand for personalized interventions 284 among patients who smoke. Personalized interventions may further increase patient compliance. For example, our study found that patients reported higher interest in taking medication (97.5% vs. 61.0%, p<.0001) when medication was personalized based on their genetics³¹. These data demonstrate the translation potential of personalized genetics in motivating patients for positive behavior change.

Unlike most current research that evaluates PRS-enabled interventions in general patient populations, our work provides a unique aspect by designing and evaluating these interventions specifically among high-risk patients who will benefit tremendously from the recommended health behaviors (lung cancer screening and smoking cessation) when general medical advice is not enough to motivate such behaviors.

294 Here we share three key design considerations for best practices. First, for 295 equitable implementation of precision health interventions, tools must be designed with 296 racial/ethnic minority communities engaged in the development process at the outset, 297 rather than solely examining whether these interventions work for these communities post 298 hoc. We engage in ongoing participatory sessions with racial and ethnic minority 299 communities and advisory boards across all phases through iterative cycles of 300 intervention development, feedback, and testing so that innovative genomics-informed tools are designed for use and benefit across diverse populations. 301

302 Second, we have chosen clinically meaningful thresholding for PRS risk categories 303 in communicating personalized risks and benefits with patients in our research. The 304 categories were selected because all participants receiving interventions in our two ongoing trials are high-risk primary care patients eligible for lung cancer screening, who 305 306 are current or previous heavy smokers. We defined lung cancer risk by the bottom 20%, 307 middle 60% and 20%, and difficulty quitting smoking by slightly more agnostic tertiles, to 308 motivate positive behavior change. We aim to follow best practices of communicating 309 uncertainties. Furthermore, we need to make decision on options of risk presentation 310 such as a continuous or categorical assignment. Importantly, we strive to be transparent 311 about the imprecision in both risk estimates and action thresholds for PRS.

312 Third, we expect to update our workflow to adapt to new GWAS and evolving 313 methodologies. As scientific knowledge rapidly progresses, outdated or inaccurate PRS predictions can hinder effective implementation. To address this challenge, a dynamic 314 315 PRS framework that allows for regular updates based on new scientific discoveries is 316 necessary. This will ensure that the PRS-based intervention remains current and aligned 317 with the latest advancements, ultimately shortening the implementation gap and maximizing its impact on preventive healthcare outcomes. Leveraging current 318 319 recommendations on genetic counseling, we have established a process and threshold to incorporate new evidence into our intervention regarding smoking cessation and lung 320 cancer risk. This process will a) adjudicate population specific new evidence regarding 321 322 genetics and biomarkers, b) evaluate its impact on changes in risk levels at personal and 323 population level, and c) develop effective communication regarding the dynamic nature 324 of genetic evidence with patients and providers.

325 There are several limitations in our work as we hope to share our experiences to help inform the knowledge pool for the best practices in creating PRS-enabled 326 327 interventions that may be disease, population, or context-specific. We have tailored our approach to our unique outcomes (lung cancer and difficulty quitting smoking), population 328 329 (patients eligible for lung cancer screening and tobacco treatment), and context (primary 330 care settings) to optimize the potential health impact of our intervention tools. Another 331 notable limitation is the underrepresentation of non-European populations in the multiancestry GWAS employed to derive the PRS weights, as well as in the UKBB used to 332 333 evaluate the PRSs. These factors may reduce the predictive power of the PRS in non-European populations. A dominance of European populations persists in most existing 334 GWAS^{32–35}, not limited to lung cancer and smoking cessation. With the burgeoning 335 emphasis on incorporating minority populations in GWAS analyses and the ongoing 336 development of new PRS approaches^{7,8,36–39} that focus on enhancing predictive power in 337 338 diverse populations, we can iteratively refine the PRS implementation in our trial to 339 synchronize with the most contemporary advancements.

340 Many guestions need to be answered in the near future. First, how can we reduce 341 the time lag from evidence to implementation? One challenge is the constant evolution of 342 evidence that identifies new biomarkers for treatment. For instance, our recent work highlights the potential of polygenic risk scores in guiding future treatment approaches⁴⁰. 343 However, despite the presence of actionable precision treatment findings, the ever-344 changing evidence base and the perception that even better data are on the horizon have 345 hindered effective implementation^{29,41}. In this proposal, we seek to overcome this 346 347 challenge by utilizing cutting-edge, biology-based metabolic and genetic markers that offer robust evidence for precision treatment. The motivation behind this approach is to 348 349 reduce the time lag from evidence generation to practical implementation, particularly in 350 the context of precision medicine, where the evidence base is continuously evolving and 351 dynamic. This affords the unique opportunity to measure and report on the time from 352 landmark publications to implementation of key findings, an approach that is being increasingly called for in translational science⁴². By leveraging state-of-the-art markers, 353 354 we aim to enhance the efficiency and effectiveness of precision treatment and ensure that 355 patients can benefit from the latest and most accurate recommendations.

356 Second, can we truly evaluate the effect of precision interventions? We expect that 357 precision interventions may activate multiple mechanistic pathways to the uptake and 358 efficacy of lung cancer screening or tobacco treatment. Understanding potential plausible 359 mechanisms is needed to improve or refine the intervention for intended outcomes and contexts. Third, can these precision interventions be scaled in the real-world clinics? 360 Evidence has shown that physicians are highly receptive to guidance on medication 361 recommendations based on biomarkers⁴³. To reduce burden, we need to leverage 362 existing EHR tools (e.g. Best Practice Advisories) to efficiently facilitate physician 363 364 prescribing^{44,45}. Understanding of mechanistic and implementation outcomes ill guide

scalable, efficient delivery components for integration into clinic workflows²⁵, trained
 embedded staff, and digital therapeutic tools to enable these PRS-informed behavioral
 interventions⁴⁶.

In conclusion, a <u>well-designed roadmap that validates the PRS, creates it using</u> TE weights, translates risk into actionable categories, communicates effectively, considers patient perspectives, and accommodates evolving science is essential for the equitable and pragmatic translation of PRS into clinical care. By addressing the barriers and implementing potential solutions at each stage, we can harness the power of PRS to improve preventive healthcare and make a meaningful difference in reducing the burden of diseases like lung cancer.

375 Acknowledgements

- We would like to thank Reeya Joseph for her editorial support with the introduction, Peter Kraft for his advice on our manuscript, and Scott Vrieze for his assistance with summary statistics for difficulty quitting. We would also like to thank and acknowledge the participants enrolled in the UK Biobank (obtained under UK Biobank resource application 52008) and GISC trial for contributing vital data to this work.
- 381

This research was supported by NIH Training Grant T32GM135117 and NSF Graduate
Research Fellowship DGE-2140743 (T.C.), R35-3CA197449, R01-HL163560, U01HG009088, and U01-HG012064 (X.L.), NIH Intramural Research Program (H.Z.), NIH
5T32-HL007776-25, R01-DA056050, R01-CA268030, P30-CA091842-19S5, P30CA091842-16S2 and P50-CA244431 (L.C.) and U19-CA203654.

387

388 Author Contributions

T.C., H.Z., and L.C. conceived the project, T.C., G.P., and L.F. carried out all data analyses
under the supervision of H.Z. and L.C. G.S. and D.J. assisted with obtaining and
processing GWAS summary statistics for difficulty quitting. T.C., G.P., H.Z., and L.C.
drafted the manuscript. All co-authors reviewed and approved the final version of the
manuscript.

394

395 **Conflicts of Interest**

Laura J. Bierut is listed as an inventor on Issued U.S. Patent 8,080,371, "Markers for Addiction" covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Michael J. Bray is an employee at ThinkGenetic, Inc. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.

- 403 All other authors have no conflict of interests to report.
- 404

405 Data and Code Availability

406 R code and plink commands, as well as accompanying data, used for analysis are 407 provided in a walkthrough available on GitHub at https://github.com/chen-tony/GREAT.

- 408
- Genotype data from the 1000 Genomes Project (Phase 3) were acquired via the plink
- 410 website <u>https://www.cog-genomics.org/plink/2.0/resources</u>. Population information were
- 411 obtained from public resources:
- 412 <u>ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/</u> and
- 413 https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000G_2504_high_coverag
- 414 <u>e/1000G_698_related_high_coverage.sequence.index</u>.

415 Figures



Mechanisms for health behavior change

Figure 1. Care Paradigm: Genomic Informed Care for Motivating High Risk 417 Individuals Eligible for Evidence-based Prevention (GREAT). The GREAT framework 418 419 is a primary care paradigm that integrates genetic and clinical risk in precision health. 420 Individuals and their providers in two upcoming trials (PRECISE and MOTIVATE) are 421 enrolled and provided with multilevel interventions (e.g. RiskProfile and PrecisionTx) to 422 promote clinical outcomes of lung cancer screening, tobacco treatment, and successful 423 smoking cessation in primary care settings. Mechanisms of health behavior changes (e.g., 424 perceived benefit, self-efficacy, and outcome expectancy) will be evaluated. During the 425 specific actionable recommendations phase, personalized shared decision-making will be facilitated by multilevel actions between patients and clinicians for better clinical 426 427 outcomes. 428 429

430

416





434

Figure 2 Roadmap for translating genetic data to a genetic risk profile as a 435 436 multilevel intervention in primary care. In step 1, enrolled participants' genetic data are analyzed by 23andMe's Clinical Laboratory Improvement Amendments (CLIA) 437 438 certified genotyping process. Imputation and quality controls are conducted through the 439 Trans-Omics for Precision Medicine (TOPMed) server to ensure the integrity and reliability of the genetic data, as well as to impute the GWAS variants. Step 2 involves 440 441 identifying available GWAS variants and weights to create the raw Polygenic Risk Scores (PRS). The PRS is adjusted for genetic ancestry using reference data such as the 1000 442 443 Genomes Project Phase 3 and applied to validation data such as the UK Biobank to 444 establish risk categories and compute odds ratios. In step 3, these scores are converted into 3 risk levels based on the established thresholds. In step 4, a report with precision 445 treatment is created and communicated to both the participant and the provider to make 446 447 informed and educated decisions. Behavioral interventionists offer personalized guidance on behavior change, leveraging the updated genetic insights. The outcome aims to 448 increase lung cancer screening orders, improve participant adherence, promote smoking 449 cessation, and highlight the benefits of tobacco treatment. 450



451

• EUR • AFR • EAS • SAS • AMR • Other

Figure 3. Cross-dataset discrimination of self-reported ethnicity via PCA 452 Projections in 1000G, UKBB and GISC. This figure illustrates the utility of principal 453 components analysis (PCA) loadings obtained from the 1000 Genomes Project Phase 3 454 455 (1000G) in discriminating ancestries within external datasets, specifically the UK Biobank (UKBB) and the Genetically Informed Smoking Cessation (GISC) trial. PCA was initially 456 457 conducted on the globally diverse genotype data of 1000G. The resultant PCA-space was 458 then used to project genotype data from both the UKBB and GISC. The scatter plot 459 displays the first and second PCs for each individual in these datasets, with points 460 distinctly marked by self-reported ethnicity.

461



463

464 Figure 4 Ancestry adjustment of PRS for lung cancer and quit difficulty PRS across ancestral populations. We showcase the adjustment process for polygenic risk scores 465 466 (PRS) for lung cancer (Panel A) and difficulty guitting smoking (Panel B) within the 1000 467 Genomes Project (1000G) and UK Biobank datasets. It displays both raw and ancestryadjusted PRS, with data points color-coded according to self-reported continental 468 ancestries. Ancestry adjustment effectively centers the PRS for different ancestries, 469 mitigating the risk of incorrect stratification due to ancestry-related biases. Dotted vertical 470 lines correspond to the 20th and 80th percentiles for lung cancer PRS distribution and 33rd 471 and 67th percentiles for difficulty guitting PRS among all 3,202 samples in the 1000 472 473 Genomes Project.



474

475 Figure 5. Risk stratification through ancestry-adjusted PRS percentiles and associated odds ratios. This figure illustrates the odds ratios (ORs) calculated for lung 476 477 cancer (Panel A) and difficulty quitting smoking (Panel B) among UK Biobank participants (N=340,154 for lung cancer and N=152,406 for smoking), based on selected cut points 478 479 within the ancestry-adjusted PRS distribution. The dashed lines mark the upper percentiles used for defining risk categories in our study: the 80th percentile for lung 480 cancer, correlating with an OR of 1.85 (95% CI: 1.58 - 2.18) and the 67th percentile for 481 guit difficulty, corresponding to an OR of 1.36 (95% CI: 1.32-1.41). 482



Figure 6. Example clinical reports for lung cancer (left) and smoking (right). We 484 485 present two genomically-informed interventions using the GREAT framework. RiskProfile 486 (left) is designed to motivate lung cancer screening and tobacco treatment among eligible patients. PrecisionTx (right) is designed to motivate precision tobacco treatment and 487 smoking cessation. Both tools utilize ancestry-adjusted PRS to stratify patients into "at 488 risk" (yellow), "high risk" (orange), and "very high risk" (red) genetic risk categories. While 489 490 RiskProfile focuses more on prevention and PrecisionTx focuses more on treatment, both interventions expand beyond personalized risk to also provide personalized benefit of 491 cancer screening and personalized medication recommendation, and use a multilevel 492 intervention design directed to both physicians and patients in clinical settings. 493 494

495 Tables

	GenoVA	eMERGE	Wisdom	PRECISE / MOTIVATE
Goal	Motivate early diagnosis	Increasing clinical actions to mitigate risk of future disease	Personalized screening frequency	Motivate lung cancer screening (LCS) / tobacco treatment
Targets				
Target population	All general Veterans' Affairs PCP* and patients	Patients in the large healthcare system	All women can sign up online	High risk PC patients (LCS eligible / smokers) and their PCPs
Condition(s)**	BrCa, PrCa, CRCa, Afib, CAD, T2D	BrCa, PrCa, CRCa, Afib, CAD, T1D, T2D, BMI, Asthma, CKD, HCL	BrCA	LC, smoking cessation
Target outcome	New diagnoses	Change screening practice or lifestyle	Screening compliance and cancer detection	LCS, tobacco tx, and smoking cessation
Polygenic Risk Scores				
Genotyping	Study team		Color genomics	23andMe
Imputation	1000 Genomes	All of Us		TOPMed
Create PRS	Top or many variants European weights Ancestry calibration	Terra cloud platform Ancestry calibration	Color genomics	Top independent variants Multi-ancestry weights Ancestry calibration
Risk Stratification	2 levels (OR of 2)	OR of 5-10		3 levels (top 20%, middle, bottom 20%) or tertiles
Intervention Design				
Risk representation	Only genetic Format of relative risk	Combined clinical + genetic Format of absolute risk	Combined clinical + genetic Format of absolute risk	Separate genetic + clinical Format of relative risk
Messaging	Average vs. elevated risk	Average vs. elevated risk	No discussion of risk Only recommend screening schedule	At risk, at high risk, or at very high risk
Behavior mechanisms targeted				Perceived risk/benefit, Self efficacy, Personal relevance

496

497 * PCP=primary care provider

** BrCa=breast cancer, PrCa=prostate cancer, CRCa=colorectal cancer, Afib=atrial
fibrillation, CAD=coronary artery/heart disease, T2D=type 2 diabetes, T1D=type 1
diabetes, BMI=body mass index/obesity, CKD=chronic kidney disease,
HCL=hypercholesterolemia, lung cancer=lung cancer

502

503 Table 1. Research on PRS use in clinical settings. We compare the PRECISE and 504 MOTIVATE trials, part of our GREAT framework, with existing PRS-informed trials: GenoVA, eMERGE, and WISDOM. Bolded text in the PRECISE / MOTIVATE column 505 506 highlight the points where our trials differ from the current trials. Namely, the PRECISE and MOTIVATE trials investigate lung cancer and smoking and will focus on high risk 507 508 patients who are smokers or eligible for lung cancer screening. We also look at lung 509 cancer screening, tobacco treatment, and smoking cessation as unique target outcomes. 510 Finally, in addition to genetic and clinical risk messaging, the two trials have a unique 511 emphasis on behavior mechanisms around lung cancer and smoking.

513 References

- 5141.Kocarnik, J. M. *et al.* Cancer Incidence, Mortality, Years of Life Lost, Years Lived515With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From5162010 to 2019. JAMA Oncol 8, 420 (2022).
- 517 2. Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of 518 polygenic risk scores. *Nature Reviews Genetics* vol. 19 581–590 Preprint at 519 https://doi.org/10.1038/s41576-018-0018-x (2018).
- Lewis, C. M. & Vassos, E. Polygenic risk scores: From research tools to clinical
 instruments. *Genome Medicine* vol. 12 Preprint at https://doi.org/10.1186/s13073020-00742-5 (2020).
- Adeyemo, A. *et al.* Responsible use of polygenic risk scores in the clinic: potential
 benefits, risks and gaps. *Nature Medicine* vol. 27 1876–1884 Preprint at
 https://doi.org/10.1038/s41591-021-01549-6 (2021).
- 526 5. Vilhjálmsson, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of 527 Polygenic Risk Scores. *Am J Hum Genet* **97**, 576–592 (2015).
- Wray, N. R., Goddard, M. E. & Visscher, P. M. Prediction of individual genetic risk
 to disease from genome-wide association studies. *Genome Res* 17, 1520–1528
 (2007).
- 531 7. Zhang, H. *et al.* A new method for multiancestry polygenic prediction improves
 532 performance across diverse populations. *Nat Genet* (2023).
- 8. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* 54, 573–580 (2022).
- 535 9. Chen, T., Zhang, H., Mazumder, R. & Lin, X. Ensembled best subset selection
 536 using summary statistics for polygenic risk prediction. *bioRxiv* (2023).
- Linder, J. E. *et al.* Returning integrated genomic risk and clinical
 recommendations: The eMERGE study. *Genetics in Medicine* 25, 100006 (2023).
- 539 11. Hao, L. *et al.* Development of a clinical polygenic risk score assay and reporting
- 540 workflow. *Nat Med* **28**, 1006–1013 (2022).
- 541 12. Shieh, Y. *et al.* Breast Cancer Screening in the Precision Medicine Era: Risk542 Based Screening in a Population-Based Trial. *J Natl Cancer Inst* **109**, djw290
 543 (2017).
- 54413.Zhang, P. *et al.* Association of smoking and polygenic risk with the incidence of545lung cancer: a prospective cohort study. *Br J Cancer* **126**, 1637–1646 (2022).
- 546 14. Kanwal, M., Ding, X.-J. & Cao, Y. Familial risk for lung cancer. *Oncol Lett* **13**, 535–
 542 (2017).
- Hung, R. J. *et al.* Assessing Lung Cancer Absolute Risk Trajectory Based on a
 Polygenic Risk Model. *Cancer Res* 81, 1607–1615 (2021).
- Lewis, A. C. F. *et al.* Getting genetic ancestry right for science and society. *Science (1979)* 376, 250–252 (2022).

Ding, Y. et al. Polygenic scoring accuracy varies across the genetic ancestry 552 17. continuum. Nature (2023). 553 554 18. Auton, A. et al. A global reference for human genetic variation. Nature 526, 68-74 555 (2015). 556 19. Ge, T. et al. Development and validation of a trans-ancestry polygenic risk score 557 for type 2 diabetes in diverse populations. Genome Med 14, 70 (2022). 558 Sudlow, C. et al. UK Biobank: An Open Access Resource for Identifying the 20. 559 Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS Med 560 **12**, e1001779 (2015). US Preventive Services Task Force. Lung Cancer: Screening. 561 21. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-562 cancer-screening (2021). 563 564 22. Agency for Healthcare Research and Quality. Clinical Guidelines and 565 Recommendations. https://www.ahrq.gov/prevention/guidelines/index.html (2021). Tobacco Use and Dependence Guideline Panel. US Department of Health and 566 23. Human Services. (2008). Tobacco Use and Dependence Guideline Panel. 567 Treating Tobacco Use and Dependence: 2008 Update. (US Department of Health 568 569 and Human Services, Rockville, MD, 2008). 570 Krist, A. H. et al. Screening for Lung Cancer. JAMA 325, 962 (2021). 24. Ayatollahi, H., Hosseini, S. F. & Hemmat, M. Integrating Genetic Data into 571 25. 572 Electronic Health Records: Medical Geneticists' Perspectives. Healthc Inform Res 573 **25**, 289 (2019). 574 26. Bourdon, J. L. et al. In-vivo design feedback and perceived utility of a genetically-575 informed smoking risk tool among current smokers in the community. BMC Med 576 Genomics 14, 139 (2021). 577 27. Ramsey, A. T. et al. Participatory Design of a Personalized Genetic Risk Tool to 578 Promote Behavioral Health. Cancer Prevention Research 13, 583–592 (2020). Ramsey, A. T. et al. Proof of Concept of a Personalized Genetic Risk Tool to 579 28. 580 Promote Smoking Cessation: High Acceptability and Reduced Cigarette Smoking. 581 Cancer Prevention Research 14, 253–262 (2021). 582 29. Ramsey, A. T. et al. Toward the implementation of genomic applications for 583 smoking cessation and smoking-related diseases. Transl Behav Med 8, 7–17 584 (2018). 30. Chen, L.-S., Baker, T. B., Ramsey, A., Amos, C. I. & Bierut, L. J. Genomic 585 586 medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. Addiction Neuroscience 7, 100083 (2023). 587 Chiu, A. et al. Most Current Smokers Desire Genetic Susceptibility Testing and 588 31. 589 Genetically-Efficacious Medication. Journal of Neuroimmune Pharmacology 13, 430-437 (2018). 590

- Seterson, R. E. *et al.* Genome-wide Association Studies in Ancestrally Diverse
 Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**,
 589–603 (2019).
- 594 33. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* 538, 161–164 (2016).
- 59634.Need, A. C. & Goldstein, D. B. Next generation disparities in human genomics:597concerns and remedies. *Trends in Genetics* **25**, 489–494 (2009).
- 598 35. Fitipaldi, H. & Franks, P. W. Ethnic, gender and other sociodemographic biases in
 599 genome-wide association studies for the most burdensome non-communicable
 600 diseases: 2005–2022. *Hum Mol Genet* 32, 520–532 (2023).
- 60136.Kachuri, L. *et al.* Principles and methods for transferring polygenic risk scores602across global populations. Nat Rev Genet (2023).
- 37. Jin, J. *et al.* MUSSEL: Enhanced Bayesian Polygenic Risk Prediction Leveraging
 Information across Multiple Ancestry Groups. *bioRxiv* (2023).
- 38. Zhou, G., Chen, T. & Zhao, H. SDPRX: A statistical method for cross-population
 prediction of complex traits. *The American Journal of Human Genetics* **110**, 13–22
 (2023).
- 39. Zhang, J. *et al.* An Ensemble Penalized Regression Method for Multi-ancestry
 Polygenic Risk Prediction. *bioRxiv* (2023).
- 40. Bray, M. *et al.* The Promise of Polygenic Risk Prediction in Smoking Cessation:
 Evidence From Two Treatment Trials. *Nicotine & Tobacco Research* 24, 1573–
 1580 (2022).
- 41. Ramsey, A. T. *et al.* Designing for Accelerated Translation (DART) of emerging
 innovations in health. *J Clin Transl Sci* 3, 53–58 (2019).
- 42. Proctor, E. *et al.* FAST: A Framework to Assess Speed of Translation of Health
 Innovations to Practice and Policy. *Global Implementation Research and Applications* 2, 107–119 (2022).
- 43. Scoville, E. A. *et al.* Precision nicotine metabolism-informed care for smoking
 cessation in Crohn's disease: A pilot study. *PLoS One* **15**, e0230656 (2020).
- 620 44. Chen, L.-S. *et al.* Low-Burden Strategies to Promote Smoking Cessation
 621 Treatment Among Patients With Serious Mental Illness. *Psychiatric Services* 69,
 622 849–851 (2018).
- 45. Ramsey, A. T. *et al.* Care-paradigm shift promoting smoking cessation treatment
 among cancer center patients via a low-burden strategy, Electronic Health
 Record-Enabled Evidence-Based Smoking Cessation Treatment. *Transl Behav Med* (2019).
- Kaphingst, K. A. *et al.* Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial. *BMC Health Serv Res* 21, 542 (2021).

- 47. Byun, J. *et al.* Cross-ancestry genome-wide meta-analysis of 61,047 cases and
 947,237 controls identifies new susceptibility loci contributing to lung cancer. *Nat*633 *Genet* 54, 1167–1177 (2022).
- 48. Saunders, G. R. B. *et al.* Genetic diversity fuels gene discovery for tobacco and
 alcohol use. *Nature* 612, 720–724 (2022).
- 63649.Chen, S. *et al.* A genome-wide mutational constraint map quantified from variation637in 76,156 human genomes. *bioRxiv* 2022.03.20.485034 (2022).
- 50. Byrska-Bishop, M. *et al.* High-coverage whole-genome sequencing of the
 expanded 1000 Genomes Project cohort including 602 trios. *Cell* 185, 34263440.e19 (2022).
- 641 51. Chen, L. *et al.* Genetic Variant in *CHRNA5* and Response to Varenicline and
 642 Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial.
 643 *Clin Pharmacol Ther* **108**, 1315–1325 (2020).
- 52. Dey, R. *et al.* Efficient and accurate frailty model approach for genome-wide
 survival association analysis in large-scale biobanks. *Nat Commun* **13**, 5437
 (2022).
- 647 53. Hinrichs, A. S. The UCSC Genome Browser Database: update 2006. *Nucleic*648 *Acids Res* 34, D590–D598 (2006).
- 649 54. Martin, A. R. *et al.* Human Demographic History Impacts Genetic Risk Prediction
 650 across Diverse Populations. *The American Journal of Human Genetics* **100**, 635–
 651 649 (2017).
- 55. Manrai, A. K. *et al.* Genetic Misdiagnoses and the Potential for Health Disparities. *New England Journal of Medicine* **375**, 655–665 (2016).
- 65456.Ochoa, A. genio: Genetics Input/Output Functions. Preprint at https://CRAN.R-655project.org/package=genio (2023).
- 65657.Price, A. L. *et al.* Principal components analysis corrects for stratification in657genome-wide association studies. Nat Genet **38**, 904–909 (2006).
- 65858.Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and659richer datasets. *Gigascience* **4**, 7 (2015).
- 59. Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify
 individuals with risk equivalent to monogenic mutations. *Nat Genet* 50, 1219–
 1224 (2018).
- 663 60. Krainc, T. & Fuentes, A. Genetic ancestry in precision medicine is reshaping the 664 race debate. *Proceedings of the National Academy of Sciences* **119**, (2022).
- 665 61. Malina, D. et al. Race and Genetic Ancestry in Medicine-A Time for Reckoning 666 with Racism. n engl j med vol. 384 (2021).

667

669 Methods

670 *Reference and validation data*

671 We conducted our analyses using data from three prominent datasets: UK Biobank (UKBB)²⁰, 1000 Genomes Project (1000G)⁵⁰, and Genetically Informed Smoking 672 Cessation Trial (GISC)⁵¹. The UKBB, a widely recognized dataset, encompasses rich 673 674 genetic and clinical data from approximately 500,000 British individuals. Our study 675 specifically used data from 340,154 unrelated multi-ancestry individuals, up to thirddegree relatives⁵², who had consented as of September 5, 2023 (**Supplementary Table** 676 1). The 1000G dataset provides a globally diverse genetic reference of 3,202 individuals, 677 with 633 Europeans (EUR), 893 Africans (AFR), 585 East Asians (EAS), 601 South 678 679 Asians (SAS), and 490 Admixed Americans (AMR). We synchronized our data by using the latest data release on hg38 reference genome and using liftOver⁵³ to convert to hg37 680 681 and align with our UKBB genotype data.

682 UKBB was used for the primary validation of our PRS due to its considerable 683 sample size and inclusion of non-European ethnicity. We used self-reported ethnicity using UKBB Field 21000, defining European (EUR) as White, British, Irish, or any other 684 white background; African (AFR) as Black, Caribbean, African, Black or Black British, or 685 686 any other black background; East Asian (EAS) as Chinese; and South Asian (SAS) as Indian, Pakistani, Bangladeshi, Asian or Asian British, or any other Asian background. 687 From the 340,154 participants, the breakdown was 318,043 EUR, 6,409 AFR, 599 EAS, 688 7,520 SAS, and 7,583 with other self-reported ethnicity. Participants' mean age was 56.6 689 690 years (SD 8.2; range 38-81 years), and the cohort was 54.1% female (183,969 691 individuals). Our lung cancer analyses included 1,830 lung cancer cases in the UKBB, 692 defined by whether a patient had at least one ICD10 code in C34.0-CD34.9 under Field 40006, and 338,334 controls with no ICD10 codes recorded (Supplementary Table 1). 693 694 The smoking cessation analysis involved 152,406 "ever-smokers", including 117,483 695 former and 34,923 current smokers, with the latter defined as having difficulty guitting 696 based on Field 20116. We excluded 186,040 'never smokers' and 1,312 participants who 697 opted for 'prefer not to answer'.

The Genetically Informed Smoking Cessation (GISC) trial is a prospective, randomized, placebo-controlled smoking cessation trial conducted at Washington University in St Louis⁵¹. This study includes 822 total individuals, all of whom are smokers. We focused on 796 individuals with genetic information, including 503 of European selfreported ethnicity, 257 African self-reported ethnicity, and 36 self-reported as "Other". GISC data was used for secondary validation, as the patient population more closely resembles the expected patients enrolled in our PRECISE and MOTIVATE trials.

706 Construction of polygenic risk scores

707 Our trial incorporates the latest findings by utilizing recently genome-wide 708 association study (GWAS) summary statistics for lung cancer⁴⁷ and difficulty quitting⁴⁸ which exclude samples from the UK Biobank to avoid overlapping with our validation data.

710 While these meta-analyses predominantly consist of individuals of European ancestry,

they also include a substantial proportion of non-European ethnic background—about 26%
for lung cancer and 21% for difficulty quitting—which enhances the generalizability of the
findings^{54,55}.

For lung cancer risk, we started with a set of 128 published SNPs found to be predictive of 5-year and lifetime cumulative risk for lung cancer¹⁵. Out of these, 101 SNPs overlapped with the published summary statistics, reference, and validation data (1000G, UKBB, and GISC), and the 23andMe genotyping array used for the trial (**Supplementary Figure 1**). These SNPs were then assigned effect sizes from the fixed-effect metaanalyses estimates in the most recent lung cancer GWAS that includes EUR, AFR, and EAS ancestry⁴⁷. Use of 23andme has been an incentive for patient participation.

For difficulty quitting, we started with 206 SNPs and SNP effects identified as predictive of smoking cessation⁴⁸. Among these 206, we identified 177 SNPs following the same filtering procedure for lung cancer and used a final list of 175 SNPs after removing 2 multiallelic SNPs.

725 The PRS construction began with the alignment of genotype data to the summary 726 statistics, ensuring consistent PRS regardless of initial reference and alternative allele 727 coding. Specifically, for any SNP G with reversed alleles, we recoded it as 2 - G to avoid discrepancies. If we were to instead change the sign of the corresponding effect size β . 728 there would be an added constant of 2β within the PRS, which can alter the overall PRS 729 730 distribution and subsequent risk stratification if patient genotypes are coded differently. 731 Once flipped SNPs were recoded, we generated the PRS as a weighted sum of SNP 732 dosages, utilizing the effect sizes β from the published summary statistics. The raw PRS 733 for an individual patient i with M SNPs was computed as

734

 $PRS_i = \beta_1 G_{i1} + \beta_2 G_{i2} + \dots + \beta_M G_{iM}.$

PRS calculations were performed using R, with genotype data input via the genio
 package⁵⁶. PRS SNPs and weights for lung cancer and difficulty quitting are provided in
 Supplementary Tables 2-3, respectively.

738

739 Principal components analysis of the 1000 Genomes Project

740 To ensure our PRS can be applied universally across ancestries, we conducted ancestry 741 adjustment using the 1000G dataset, which provides a representative cross-section of 742 the five major global superpopulations: AFR, AMR, EAS, EUR and SAS¹⁸. Principal 743 components analysis (PCA) is popular tool in ancestry inference, as it can capture 744 continental genetic diversity and provide a continuous, label-free quantification of genetic ancestry^{16,17,57}. We performed PCA on all 3,202 1000G samples, using 55,248 SNPs that 745 are shared among the recommended SNPs set by gnomAD⁴⁹, 1000G reference data, 746 747 UKBB and GISC validation data, and the 23andMe genotyping array used for the trial (Error! Reference source not found.). PCA was performed using plink 2.0⁵⁸ with the 748

following command to generate the top five PCs: "--pca allele-wts 5". This process resulted in a set of loadings or weights for each of the 55,248 SNPs corresponding to each principal component. We then applied these loadings to genotype data from 1000G, UKBB, and GISC within plink 2.0, employing the command: "--score [i] [j] header cols=+scoresums,-scoreavgs,-dosagesum,-nallele --score-col-nums [k1]-[k2]" to generate the PC scores.

755

764

756

Standardizing PRS distributions across the continuum of genetic ancestry

We standardized the PRS distributions for lung cancer and difficulty quitting using data from the 1000G dataset, employing a regression-based method to adjust for distributional differences across ancestries^{11,19,59}. This adjustment process involves two key steps:

First, we conducted a linear regression of the raw PRS against the top five PCs derived from the PCA, such that the PRS of individual i is a linear model of their PCs with random noise:

$$PRS_i = \alpha_0 + \alpha_1 PC_{i1} + \alpha_2 PC_{i2} + \dots + \alpha_5 PC_{i5} + \epsilon_i^{mean}$$

We obtained an estimated intercept $\widehat{\alpha_0}$, and weights $(\widehat{\alpha_1}, \dots, \widehat{\alpha_5})$ for each PC. The residuals of the raw PRS, accounting for the linear effects of the PCs, were calculated as: $R_i = PRS_i - \widehat{\alpha_1}PC_{i1} - \dots - \widehat{\alpha_5}PC_{i5}$.

This first step is designed to remove mean differences in the PRS distribution across ancestries. Subsequently, we used the square residuals R_i^2 as a measure for PRS variance, and ran a secondary linear regression model with:

771
$$R_i^2 = \gamma_0 + \gamma_1 P C_{i1} + \gamma_2 P C_{i2} + \dots + \gamma_5 P C_{i5} + \epsilon_i^{var}.$$

From this, we derived a second estimated intercept ($\hat{\gamma}_0$) and a new set of weights ($\hat{\gamma}_1, \dots, \hat{\gamma}_5$) for each PC's effect on the variance of the PRS. The final ancestry-adjusted PRS for each individual *i* was then computed as:

775

$$PRS_i^{cal} = \frac{PRS_i - \widehat{\alpha_0} - \widehat{\alpha_1}PC_{i1} - \dots - \widehat{\alpha_5}PC_{i5}}{\sqrt{\widehat{\gamma_0} + \widehat{\gamma_1}PC_{i1} + \widehat{\gamma_2}PC_{i2} + \dots + \widehat{\gamma_5}PC_{i5}}}$$

By scaling the residuals with the fitted values from the second regression, we
standardized the variance of the PRS distribution across ancestries to mean 0 and
variance 1.

We validated this ancestry adjustment procedure in the UKBB and GISC datasets by applying the PC coefficients $(\widehat{\alpha_1}, \dots, \widehat{\alpha_5}, \widehat{\gamma_1}, \dots, \widehat{\gamma_5})$ to the raw PRS. This ancestryadjusted PRS accurately reflects an individual's genetic risk independent of their ancestry, facilitating a unified risk stratification methodology. This is especially crucial for individuals with admixed or unknown ancestry, for whom discrete ancestry-specific prediction models may be unsuitable or invalid^{4,16,36,60,61}.

785

786 *Risk categories determination*

To stratify patients by genetic risk for lung cancer and difficulty quitting, we calculated odds ratios (OR). These ratios compare the probability of an outcome occurring in individuals within a percentile range p (i.e. 80-100%) of the ancestry-adjusted PRS distribution with the probability of the same outcome occurring in individuals within another percentile range q (i.e. 0-20%).

792
$$OR_{pq} = \frac{P(Y=1|PRS \in p)/P(Y=0|PRS \in p)}{P(Y=1|PRS \in q)/P(Y=0|PRS \in q)}$$

Following the determination of the desired OR for each health outcome, we established cut points within the PRS distribution to categorize individuals into three distinct risk groups: "at risk", "high risk", and "very high risk".

796 We chose clinically meaningful thresholds to define three risk categories - "at risk", 797 "high risk", and "very high risk" – in communicating personalized risks and benefits with 798 patients in our research. We use these category names because all participants in these 799 two ongoing trials are high-risk patients eligible for lung cancer screening with active 800 heavy smoking. For lung cancer, we categorize patients by the bottom 20%, middle 60%, 801 and top 20%. For difficulty guitting, we divide the PRS distribution into thirds – using the 802 bottom, middle, and top 33%. Since difficulty quitting is a behavior trait with no established 803 absolute risk rates like cancer, we use these percentiles to provide slightly more agnostic 804 risk information.

For our ancestry-adjusted PRS, we use the distribution among all 1000G samples to set percentile ranges and evaluate corresponding odds ratios among UKBB participants. For comparison, we also evaluate odds ratios using ancestry-matched raw PRS distributions, i.e. European-only 1000G PRS distribution for self-reported European UKBB participants. For UKBB participants with "Other" ethnic background, we use the raw PRS distribution among all 1000G samples, rather than matching to a specific group.